Valganciclovir - adult tablets

For CrCl >=60, induction is 900 mg twice daily and maintenance/prevention 900 mg daily. At 40-59, use 450 mg twice daily or 450 mg daily, respectively. At 25-39, use 450 mg daily or every two days. At 10-24, use 450 mg every two days or twice weekly. Below 10 on hemodialysis, the label provides no tablet dose and says the tablets should not be used; it directs clinicians to appropriately adjusted ganciclovir. Monitor kidney function and blood counts. Take with food and do not crush or split tablets. Institutional dialysis regimens are displayed separately, not called label-approved.

For intermittent HD, UCSF lists CMV treatment as 450 mg orally once now and after HD; prophylaxis is 450 mg twice weekly. For continuous HD it lists treatment 450 mg daily and prophylaxis 450 mg every 48 hours. IV ganciclovir is preferred when initiating treatment during unstable renal function or dialysis. Give with food. These are institution-specific regimens outside the label's adult tablet-HD recommendation. Confirm actual dialysis settings and specialist monitoring rather than treating continuous HD and intermittent HD as interchangeable.

Participants received 450 mg enterally every 24 hours for prophylaxis. Eight of ten achieved the proposed ganciclovir trough target of at least 0.60 microgram/mL; no neutropenia was documented, while significant thrombocytopenia occurred in six. The authors suggest daily dosing may be needed to achieve the desired exposure. This small pharmacokinetic study did not establish comparative clinical efficacy, universal safety or a prescription for every CRRT setting. Its daily schedule differs from UCSF's displayed continuous-HD prophylaxis interval; reconcile modality, clearance and monitoring with specialists.